Literature DB >> 18814248

A pilot study on the distribution of human papillomavirus genotypes and HPV-16 variants in cervical neoplastic lesions from Ecuadorian women.

Maria Lina Tornesello1, Luigi Buonaguro, Sergio Izzo, Guillermo Lopez, Ximena Vega, Claudio Francisco Maldonado Reyes, Franco Maria Buonaguro.   

Abstract

Human papillomaviruses (HPVs) are the cause of cervical intraepithelial neoplasia and invasive carcinomas of the uterine cervix. The distribution of specific HPV genotypes varies greatly across populations and HPV surveys have been performed in different geographical regions in order to apply appropriate vaccine strategies. The aim of this study was to determine the spectrum of HPV genotypes and HPV-16 variants among women with cervical lesions living in Ecuador. A total of 71 cases have been analyzed, including 32 chronic cervicitis, 29 cervical intraepithelial neoplasia grade 1, and 10 cervical intraepithelial neoplasia grade 2-3. HPV sequences were detected by broad spectrum consensus-primer-pairs MY09/MY11 and GP5+/GP6+-based polymerase chain reaction and characterized by nucleotide sequence analysis. Overall, 31 (43.7%) cases were HPV positive with prevalence rates of 37.5%, 44.8%, and 60% in patients with chronic cervicitis, cervical intraepithelial neoplasia grade 1 and cervical intraepithelial neoplasia grade 2-3, respectively. Among the positive cases, the most common genotypes were HPV 16 (64.5%) and HPV 81 (29%) followed by HPV 31, 53, 56, and 58, in descending order of prevalence. Seventeen (85%) HPV-16 isolates were classified as European and three (15%) as African-1 variant on the basis of nucleotide signature present within the MY09/MY11 L1 sequence. The results suggest that HPV 16 has a very high prevalence among women with cervical lesions in Ecuador; therefore, an effective HPV-16 based vaccine should prevent the development of cervical cancer in a large proportion of Ecuadorian women. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18814248     DOI: 10.1002/jmv.21317

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  HPV types and variants among cervical cancer tumors in three regions of Tunisia.

Authors:  Keris KrennHrubec; Karima Mrad; Badreddine Sriha; Farhat Ben Ayed; Danielle M Bottalico; Janae Ostolaza; Benjamin Smith; Tatyana Tchaikovska; Amr S Soliman; Robert D Burk
Journal:  J Med Virol       Date:  2011-04       Impact factor: 2.327

2.  Prevalence of High-Risk Genotypes of Human Papillomavirus: Women Diagnosed with Premalignant and Malignant Pap Smear Tests in Southern Ecuador.

Authors:  Paola Dalgo Aguilar; Cisne Loján González; Ana Córdova Rodríguez; Katherine Acurio Páez; Ana Paulina Arévalo; Jana Bobokova
Journal:  Infect Dis Obstet Gynecol       Date:  2017-06-22

3.  Frequency and distribution of HPV genotypes in 800 genital samples of Ecuadorian men and women from the city of Guayaquil.

Authors:  Gustavo David García Muentes; Marcia Adelaida Mendoza García; Ramiro Israel Burgos Galárraga; Kleber Ollague; Cynthia Vargas Wachter; Juan Carlos Ruiz Cabezas
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2019-08-19       Impact factor: 1.846

4.  Cancer mortality and quantitative oil production in the Amazon region of Ecuador, 1990-2010.

Authors:  Suresh H Moolgavkar; Ellen T Chang; Heather Watson; Edmund C Lau
Journal:  Cancer Causes Control       Date:  2013-11-30       Impact factor: 2.506

5.  Distribution of HPV Genotypes and Involvement of Risk Factors in Cervical Lesions and Invasive Cervical Cancer: A Study in an Indian Population.

Authors:  Shikha Srivastava; U P Shahi; Arti Dibya; Sadhana Gupta; Jagat K Roy
Journal:  Int J Mol Cell Med       Date:  2014

6.  A pilot study on the identification of human papillomavirus genotypes in tongue cancer samples from a single institution in Ecuador.

Authors:  G M Delgado Ramos; T G Cotter; L Flor Ramos; V Torres Floril; G A Ramos Martinez; J C Ruiz-Cabezas
Journal:  Braz J Med Biol Res       Date:  2018-10-08       Impact factor: 2.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.